CUSIP NO. G8807B106
SCHEDULE 13G/A
PAGE 1 OF 10 PAGES
===============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
THERAVANCE BIOPHARMA, INC.
-------------------------------------------------------------------------------
(Name of Issuer)
Ordinary Share $0.00001 Par Value
-------------------------------------------------------------------------------
(Title of Class of Securities)
G8807B106
-------------------------------------------------------------------------------
(CUSIP Number)
December 31, 2022
-------------------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP NO. G8807B106
SCHEDULE 13G/A
PAGE 2 OF 10 PAGES
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION
NO. OF ABOVE PERSON
WEISS ASSET MANAGEMENT LP
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(A) [ ]
(B) [ ]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
0
NUMBER OF --------------------------------------------------
SHARES 6. SHARED VOTING POWER
BENEFICIALLY
OWNED BY 7,457,060
EACH --------------------------------------------------
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON
WITH: 0
--------------------------------------------------
8. SHARED DISPOSITIVE POWER
7,457,060
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,457,060
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* [ ]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11.09%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
IA – Investment Adviser
CUSIP NO. G8807B106
SCHEDULE 13G/A
PAGE 3 OF 10 PAGES
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION
NO. OF ABOVE PERSON
BIP GP LLC
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(A) [ ]
(B) [ ]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
0
NUMBER OF --------------------------------------------------
SHARES 6. SHARED VOTING POWER
BENEFICIALLY
OWNED BY 4,628,074
EACH --------------------------------------------------
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON
WITH: 0
--------------------------------------------------
8. SHARED DISPOSITIVE POWER
4,628,074
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,628,074
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* [ ]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.88%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
00 – Limited Liability Company
CUSIP NO. G8807B106
SCHEDULE 13G/A
PAGE 4 OF 10 PAGES
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION
NO. OF ABOVE PERSON
WAM GP LLC
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(A) [ ]
(B) [ ]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
0
NUMBER OF --------------------------------------------------
SHARES 6. SHARED VOTING POWER
BENEFICIALLY
OWNED BY 7,457,060
EACH --------------------------------------------------
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON
WITH: 0
--------------------------------------------------
8. SHARED DISPOSITIVE POWER
7,457,060
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,457,060
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* [ ]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11.09%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
HC – Parent Holding Company/Control Person
CUSIP NO. G8807B106
SCHEDULE 13G/A
PAGE 5 OF 10 PAGES
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION
NO. OF ABOVE PERSON
ANDREW M. WEISS, PH.D.
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(A) [ ]
(B) [ ]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
USA
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
0
NUMBER OF --------------------------------------------------
SHARES 6. SHARED VOTING POWER
BENEFICIALLY
OWNED BY 7,457,060
EACH --------------------------------------------------
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON
WITH: 0
--------------------------------------------------
8. SHARED DISPOSITIVE POWER
7,457,060
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,457,060
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* [ ]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11.09%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
HC – Parent Holding Company/Control Person
CUSIP NO. G8807B106
SCHEDULE 13G/A
PAGE 6 OF 10 PAGES
ITEM 1.
(a) Name of Issuer: THERAVANCE BIOPHARMA, INC.
------------------------------------------------
(b) Address of Issuer's Principal Executive Offices:
PO Box 309
Ugland House, South Church Street
George Town, Grand Cayman, Cayman Islands KY1-1104
------------------------------------------------
ITEM 2.
(a) and (c): Name and Citizenship of Persons Filing:
(i) BIP GP LLC, a Delaware limited liability company (“BIP GP”).
(ii) Weiss Asset Management LP, a Delaware limited partnership ("Weiss Asset Management").
(iii) WAM GP LLC, a Delaware limited liability company (“WAM GP”).
(iv) Andrew M. Weiss, Ph.D., a United States citizen (“Andrew Weiss”).
(b): Address of Principal Business Office:
BIP GP, Weiss Asset Management, WAM GP, and Andrew Weiss have a business
address of 222 Berkeley St., 16th floor, Boston, Massachusetts 02116
(d) Title of Class of Securities: Ordinary Share $0.00001 Par Value
-------------------------------------
(e) CUSIP Number: G8807B106
------------------
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B), CHECK
WHETHER THE PERSON FILING IS A:
(a) [ ] Broker or Dealer registered under Section 15 of the Act
(15 U.S.C. 78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [ ] Insurance Company as defined in section 3(a)(19) of the Act
(15 U.S.C. 78c).
(d) [ ] Investment Company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8).
(e) [ ] Investment Adviser registered under section 203 of the Investment
Advisers Act or under the laws of any State
(f) [ ] Employee Benefit Plan, Pension fund which is subject to the
provisions of the Employee Retirement Income Security Act of
1974 or Endowment Fund; see Section 240.13d-1(b)(1)(ii)(F)
(g) [ ] A Parent Holding Company or control person, in accordance with
Section 240.13d-1(b)(ii)(G)
(h) [ ] A Savings Association as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813)
(i) [ ] A Church Plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the Investment
Company Act of 1940 (15 U.S.C. 80a-3)
(j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J)
CUSIP NO. G8807B106
SCHEDULE 13G/A
PAGE 7 OF 10 PAGES
ITEM 4. OWNERSHIP
BIP GP*
(a) Amount Beneficially Owned: 4,628,074
-------------------------------------------
(b) Percent of Class: 6.88%
----------------------------------------------------
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 0
-----------------------
(ii) shared power to vote or to direct the vote: 4,628,074
---------------------
(iii) sole power to dispose or to direct the disposition of: 0
----------
(iv) shared power to dispose or to direct the disposition of: 4,628,074
----------
WEISS ASSET MANAGEMENT*
(a) Amount Beneficially Owned: 7,457,060
-------------------------------------------
(b) Percent of Class: 11.09%
----------------------------------------------------
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 0
-----------------------
(ii) shared power to vote or to direct the vote: 7,457,060
---------------------
(iii) sole power to dispose or to direct the disposition of: 0
----------
(iv) shared power to dispose or to direct the disposition of: 7,457,060
----------
WAM GP*
(a) Amount Beneficially Owned: 7,457,060
-------------------------------------------
(b) Percent of Class: 11.09%
----------------------------------------------------
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 0
-----------------------
(ii) shared power to vote or to direct the vote: 7,457,060
---------------------
(iii) sole power to dispose or to direct the disposition of: 0
----------
(iv) shared power to dispose or to direct the disposition of: 7,457,060
----------
ANDREW M. WEISS, PH.D.*
(a) Amount Beneficially Owned: 7,457,060
-------------------------------------------
(b) Percent of Class: 11.09%
----------------------------------------------------
(c) Number of shares as to which such person has:
CUSIP NO. G8807B106
SCHEDULE 13G/A
PAGE 8 OF 10 PAGES
(i) sole power to vote or to direct the vote: 0
------------------------
(ii) shared power to vote or to direct the vote: 7,457,060
-----------------------
(iii) sole power to dispose or to direct the disposition of: 0
-----------
(iv) shared power to dispose or to direct the disposition of: 7,457,060
-----------
-----------------------
* Shares reported for BIP GP include shares beneficially owned by a private investment partnership (the “Partnership”) of which BIP GP is the sole general partner. Weiss Asset Management is the sole investment manager to the Partnership and private investment funds (“Funds”). WAM GP is the sole general partner of Weiss Asset Management. Andrew Weiss is the managing member of WAM GP and BIP GP. Shares reported for WAM GP, Andrew Weiss and Weiss Asset Management include shares beneficially owned by the Partnership (and reported above for BIP GP) and the Funds.
Each of BIP GP, WAM GP, Weiss Asset Management, and Andrew Weiss disclaims beneficial ownership of the shares reported herein as beneficially owned by each except to the extent of their respective pecuniary interest therein. The percent of class computations are based on 67,249,945 Ordinary Share $0.00001 Par Value, issued and outstanding as of October 31, 2022, as calculated from the Form 10-Q of the Issuer, which was filed with the SEC on November 9, 2022, and the Form SC TO-I/A of the Issuer, which was filed with the SEC on November 18, 2022.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following [ ].
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Brookdale International Partners, L.P., a US limited partnership, for which Weiss Asset Management serves as investment manager, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than five percent of the Ordinary share, par value $0.00001 per share of the Issuer.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL
PERSON
See Item 4.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not Applicable
CUSIP NO. G8807B106
SCHEDULE 13G/A
PAGE 9 OF 10 PAGES
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
ITEM 11. MATERIALS TO BE FILED AS EXHIBITS
Exhibit 1
Joint Filing Agreement
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I hereby
certify that the information set forth in this statement is true, complete and
correct.
Dated: February 10, 2023
WEISS ASSET MANAGEMENT LP
By: /s/ Mary Ferruolo
-----------------------------------
Mary Ferruolo, Authorized Signatory
BIP GP LLC
By: /s/ Mary Ferruolo
-----------------------------------
Mary Ferruolo, Authorized Signatory
WAM GP LLC
By: /s/ Mary Ferruolo
-----------------------------------
Mary Ferruolo, Authorized Signatory
ANDREW M. WEISS, PH.D.
By: /s/ Mary Ferruolo
-----------------------------------
Mary Ferruolo, Attorney-in-Fact for Andrew Weiss**
*** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on February 3, 2023 in respect of its holding in DEEP MEDICINE ACQUISITION CORP.
CUSIP NO. G8807B106
SCHEDULE 13G/A
PAGE 10 OF 10 PAGES
Exhibit 1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, Weiss Asset Management LP, BIP GP LLC, WAM GP LLC, and Andrew M. Weiss, hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G and/or 13D (including any and all amendments thereto) with respect to the Ordinary Share $0.00001 Par Value of THERAVANCE BIOPHARMA, INC., and further agree that this Joint Filing Agreement, as may be amended from time to time, shall be included as an Exhibit to such joint filings.
The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and/or 13D and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.
This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of June 16, 2022.
WEISS ASSET MANAGEMENT LP
By: /s/ Georgiy Nikitin
-----------------------------------
Georgiy Nikitin, Chief Compliance Officer
BIP GP LLC
By: /s/ Georgiy Nikitin
-----------------------------------
Georgiy Nikitin, Chief Compliance Officer
WAM GP LLC
By: /s/ Georgiy Nikitin
-----------------------------------
Georgiy Nikitin, Chief Compliance Officer
ANDREW M. WEISS, PH.D.
By: /s/ Georgiy Nikitin
-----------------------------------
Georgiy Nikitin, Attorney-in-Fact for Andrew Weiss**
_____
** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on January 25, 2017 in respect of its holding in Quinpario Acquisition Corp. 2.